Nicholas Koroneos, DO
Neurology · Little River, SCNPI 1134622913
Payments from drug & device makers
Across 183 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$459
- Novartis$385
- UCB, Inc.$352
- Teva Pharmaceuticals USA, Inc.$313
- Acadia Pharmaceuticals Inc$282
- Lundbeck LLC$223
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,21996%
- Education$1574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $459 |
| Novartis | 15 | $385 |
| UCB, Inc. | 12 | $352 |
| Teva Pharmaceuticals USA, Inc. | 13 | $313 |
| Acadia Pharmaceuticals Inc | 10 | $282 |
| Lundbeck LLC | 10 | $223 |
| TG Therapeutics, Inc. | 11 | $213 |
| Amneal Pharmaceuticals LLC | 6 | $187 |
| AstraZeneca | 4 | $167 |
| SK Life Science, Inc. | 6 | $162 |
| Lilly USA, LLC | 8 | $161 |
| Averitas Pharma Inc. | 4 | $134 |
| Novus Surgical Consultants | 1 | $133 |
| Neurocrine Biosciences, Inc. | 5 | $130 |
| Bristol Myers Squibb | 7 | $129 |
| Pfizer | 6 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Amgen(2 entities) | 4 | $90 |
| Alnylam Pharmaceuticals Inc. | 4 | $83 |
| Tanabe Pharma America, Inc. | 2 | $73 |
| Biogen | 3 | $71 |
| Argenx US, Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Acorda Therapeutics, Inc | 2 | $41 |
| Sanofi | 1 | $40 |
| CSL Behring | 1 | $34 |
| Tonix Medicines, Inc. | 1 | $30 |
| EMD Serono, Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$115
- Austedo XR$113
- CREXONT$106
- ULTOMIRIS$100
How this compares
$4,376 in reported general payments places this provider in the 65th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 14 | $84,155 |
| Emgality PenGalcanezumab-Gnlm | 29 | $26,675 |
| QuliptaAtogepant | 18 | $23,760 |
| Nurtec OdtRimegepant Sulfate | 16 | $22,028 |
| Memantine Hcl | 167 | $5,828 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 118 | $5,322 |
| Levetiracetam | 97 | $2,663 |
| Propranolol Hcl ErPropranolol Hcl | 52 | $2,242 |
| Rivastigmine | 15 | $1,819 |
| Donepezil Hcl | 166 | $1,732 |
| Gabapentin | 74 | $1,629 |
| Pregabalin | 63 | $1,589 |
| Primidone | 52 | $1,173 |
| Clonazepam | 50 | $934 |
| Propranolol Hcl | 57 | $933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $313 | $84,15514 claims |
| AbbVieQulipta | $459 | $23,76018 claims |
| PfizerNurtec Odt | $102 | $22,02816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 270 neurology providers in South Carolina.
Other neurology in Little River
- Olinda SpencerLittle River$44K
- Kushagra MainiLittle River$15K
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.